{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":2,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT03375320","nct_id":"NCT03375320","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03375320. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study.","label":"Arm I (cabozantinib S-malate)","type":"EXPERIMENTAL"},{"description":"Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.","label":"Arm II (placebo)","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-09-01","type":"ESTIMATED"},"conditions":["Functioning Pancreatic Neuroendocrine Tumor","Intermediate Grade Lung Neuroendocrine Neoplasm","Locally Advanced Digestive System Neuroendocrine Neoplasm","Locally Advanced Digestive System Neuroendocrine Tumor G1","Locally Advanced Lung Neuroendocrine Neoplasm","Locally Advanced Pancreatic Neuroendocrine Tumor","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm","Low Grade Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Tumor","Lung Neuroendocrine Tumor G2","Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Digestive System Neuroendocrine Tumor G1","Metastatic Lung Neuroendocrine Neoplasm","Metastatic Lung Neuroendocrine Tumor","Metastatic Pancreatic Neuroendocrine Neoplasm","Metastatic Pancreatic Neuroendocrine Tumor","Metastatic Thymus Neuroendocrine Neoplasm","Neuroendocrine Neoplasm","Neuroendocrine Tumor","Neuroendocrine Tumor G2","Non-Functioning Pancreatic Neuroendocrine Tumor","Pancreatic Serotonin-Producing Neuroendocrine Tumor","Thymus Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Lung Neuroendocrine Neoplasm","Unresectable Pancreatic Neuroendocrine Neoplasm","Unresectable Thymus Neuroendocrine Neoplasm"],"enrollment":{"count":298,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Cabozantinib S-malate","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Placebo Administration","type":"OTHER"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"X-Ray Imaging","type":"PROCEDURE"}],"last_update":"2026-09-22","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"36 months"}],"references":[{"citation":"Strosberg JR, Zemla T, Geyer S, Pulsipher S, Ou FS, Behr S, Raj N, Vijayvergia N, Dasari A, O'Reilly EM, Meyerhardt JA, Wolin EM, Halfdanarson TR, Chan JA. Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Endocr Relat Cancer. 2026 Jan 24;33(1):e250415. doi: 10.1530/ERC-25-0415. Print 2026 Jan 1.","pmid":"41524552","type":"DERIVED"},{"citation":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13;392(7):653-665. doi: 10.1056/NEJMoa2403991. Epub 2024 Sep 16.","pmid":"39282913","type":"DERIVED"},{"citation":"Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol. 2020 Nov;21(11):1395-1397. doi: 10.1016/S1470-2045(20)30560-X. No abstract available.","pmid":"33152282","type":"DERIVED"}],"start_date":{"date":"2018-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","url":"https://clinicaltrials.gov/study/NCT03375320"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03375320"}